Medera is focused on eradicating difficult-to-treat and incurable cardiovascular diseases by advancing next-generation gene- and cell-based therapies.
Company Highlights
Medera is a clinical-stage biopharmaceutical company with two solely owned operating subsidiaries: Novoheart and Sardocor. The following graphic highlights some of the key numbers you should know.
Novoheart is focused on pre-clinical disease modeling and drug discovery using our proprietary and commercially available human mini-Heart platform of cardiac screening assays. Our founders have over 25 years of experience pioneering the field of human mini-heart engineering, including genetically engineering the first human heart cells from pluripotent stem cells, and developing the first and only commercially available human heart-in-a-jar technology. Boasting the longest corporate history and most comprehensive technology platform for cardiac screening, our successes thus far include new disease models and efficacy data accepted by the FDA in accordance with the Modernization Act 2.0 and in partnership with Sardocor, providing major savings in terms of development time and cost for bringing new drugs to clinical trials.
Sardocor is focused on clinical development of novel cardiovascular cell and gene therapies and related technologies. Founded by scientific visionaries who started the field of Cardiac Gene Therapy over three decades ago, Sardocor has developed an extensive pipeline of gene therapy and small molecule candidates. Where appropriate, our gene therapy drug products are administered as a simple out-patient procedure using our proprietary heart-specific delivery methodology. Sardocor is conducting three FDA-approved experimental medicine clinical trials, including two first-in-human trials for incurable heart diseases, based in part on efficacy and dosing data from Novoheart’s human mini-Heart assays.
